February 10, 2026 — RNews

#chemoradiotherapy — Tuesday, February 10, 2026 (1 items)

hot top new

← prev day next day →

0

Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial. (bmj.com)

You R … Chen MY BMJ 2026-02-10

#cancer #clinical trial #immunotherapy #chemoradiotherapy #pd-1